Roche CEO Severin Schwan (via Reuters)
September 3, 2019 06:26 AM EDTUpdated 06:52 AM
Deals

Roche stays mum about FTC, CMA re­views as $4.3B Spark deal faces yet an­oth­er de­lay. What's up?

Amber Tong

Just what ex­act­ly is hold­ing up Roche’s $4.3 bil­lion ac­qui­si­tion of Spark Ther­a­peu­tics?

That’s the ques­tion that Spark in­vestors are pon­der­ing as the Swiss drug­mak­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

A service from the Financial Times